Home Cart Sign in  
Chemical Structure| 1229194-11-9 Chemical Structure| 1229194-11-9

Structure of Edoxaban tosylate monohydrate
CAS No.: 1229194-11-9

Chemical Structure| 1229194-11-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Edoxaban tosylate is a selective factor Xa inhibitor with Ki of 0.561 nM, > 10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.

Synonyms: DU-176b monohydrate; DU-176b

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Edoxaban tosylate monohydrate

CAS No. :1229194-11-9
Formula : C31H40ClN7O8S2
M.W : 738.27
SMILES Code : O=C(NC1=NC=C(Cl)C=C1)C(N[C@@H]2[C@H](NC(C(S3)=NC4=C3CN(C)CC4)=O)C[C@@H](C(N(C)C)=O)CC2)=O.O=S(C5=CC=C(C)C=C5)(O)=O.[H]O[H]
Synonyms :
DU-176b monohydrate; DU-176b
MDL No. :MFCD28400751
InChI Key :PSMMNJNZVZZNOI-SJILXJHISA-N
Pubchem ID :25022378

Safety of Edoxaban tosylate monohydrate

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H372-H410
Precautionary Statements:P260-P264-P273-P301+P312-P305+P351+P338-P314
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Target
  • Factor Xa

    Factor Xa, Ki:0.561 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Human plasma 0.25 μg/mL, 0.5 μg/mL, 1.5 μg/mL, 3 μg/mL 60 minutes To evaluate the effect of EDX DPI formulations on the clotting process. Results showed a significant decline in maximum turbidity with increasing drug concentration, indicating reduced clotting rates and altered clot structure. PMC8463814
HK-2 cells 0.1–100 μM 3 hours To evaluate the antioxidant effect of edoxaban on FXa-, IS-, and AII-induced intracellular ROS production. Results showed that edoxaban significantly inhibited ROS production induced by FXa, IS, and AII. PMC6747217

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57B/6J mice Atrial fibrillation model Oral 0.03 mg/d Once daily for 14 days To evaluate the effects of edoxaban on myocardial fibrosis, inflammation, blood lipids, and coagulation function in AF mice, found that edoxaban significantly reduced myocardial fibrosis, inflammation, and blood lipid levels, and improved coagulation function. PMC9204214
Male C57Bl/6N mice Transient middle cerebral artery occlusion model Oral gavage 3.3 mg/kg body weight Three times administration Edoxaban significantly reduced infarct volumes, improved neurological outcome, and attenuated brain tissue inflammation on day 1 and day 7. PMC8464921
C57B/6J mice Atrial fibrillation model Oral 0.03 mg/d Once daily for 14 days Edoxaban effectively prevented atrial fibrillation and coagulation by reducing inflammation, lipids, and fibrosis via HBG1/HBD biomarkers, and the effect was superior to that of rivaroxaban. PMC9204214
Male C57Bl/6N mice Transient middle cerebral artery occlusion model Oral gavage 3.3 mg/kg body weight Three administrations at 72, 48, and 24 hours before tMCAO To assess the protective effect of edoxaban on acute ischemic stroke, results showed edoxaban significantly reduced infarct volumes and improved neurological outcome PMC8464921

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.35mL

0.27mL

0.14mL

6.77mL

1.35mL

0.68mL

13.55mL

2.71mL

1.35mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories